Impact of iris color on uveal melanoma-related outcomes in 7245 patients at a single ocular oncology center.

PURPOSE: To determine the relationship between iris color and uveal melanoma (UM)-related metastasis and death in a large cohort of patients from a single ocular oncology center. DESIGN: Retrospective case series. SUBJECTS: Patients diagnosed with UM between February 1971 and August 2007. METHODS: Patient information was obtained from chart documentation. MAIN OUTCOME MEASURES: UM-related metastasis and death. RESULTS: Out of 7245 patients, iris color was blue in 3702 (51%), green in 1458 (20%), and brown in 2085 (29%). Mean age was 58 ± 15 years and mean tumor thickness was 5.5 ± 3.3 millimeters. Some clinical features differed between iris color groups, with the blue irides group having a larger proportion of post-equatorial tumors with significantly closer proximity to the foveola and optic disc compared to the brown irides group. At a mean follow-up of 75 months, there was no statistically significant difference in metastasis between the various iris color groups. On univariate analysis, those with blue irides showed a higher incidence of UM-related death compared to the green and brown irides groups (8.3%, 5.9% and 7.5% respectively, p value = 0.02). Kaplan-Meier event free survival from UM-related death significantly differed only between the blue and green irides groups (p value = 0.007) with the green irides group showing the highest survival. However, on multivariate analysis, iris color was not predictive of UM-related death. CONCLUSION: Iris color was not predictive of UM-related metastasis or death. However, Kaplan-Meier survival at 20 years was poorest for blue irides group compared to green.

Patient perspectives on ocular oncology care at hybrid telehealth satellite offices.

OBJECTIVE: To assess patient satisfaction with the hybrid telehealth model in patients undergoing follow-up care in ocular oncology. DESIGN: Retrospective survey study. PARTICIPANTS: All patients who visited 1 of 2 satellite telehealth offices between July 2021 and October 2022 for their follow-up ocular oncology appointment. METHODS: A 13-question online survey was completed for outcome measures of patient demographics, patient satisfaction with the satellite offices, and overall patient experience with telehealth. RESULTS: The survey response rate was 32% (203 of 632). The mean patient age was 65 years (median, 65 years), and 119 patients (58%) were female. A comparison (suburban satellite vs urban in-person office) revealed that the suburban satellite office had less difficulty in travel (3% vs 47%; p < 0.001) and less time commitment (<1 hour) for travel to the office (58% vs 23%; p < 0.001). On a scale (i.e., poor, fair, good, or excellent), the percentage of patients reported the following parameters as good or excellent: ease of finding satellite office (95%), check-in (94%), and time spent waiting for the doctor (72%). On a scale (i.e., extremely dissatisfied to extremely satisfied), the percentage of patients reported being extremely satisfied to the following parameters: the staff (81%) and the office overall (65%). Most patients (90%) would use this telehealth model for future visits (p < 0.0001), and 86% would recommend it to a friend (p < 0.0001). CONCLUSION: In this study on a hybrid telehealth satellite office model for ocular oncology follow-up examinations, patient satisfaction was high, most patients would use this form of examination in the future.

Relationship between Fitzpatrick Skin Type and The Cancer Genome Atlas Classification with Melanoma-Related Metastasis and Death in 854 Patients at a Single Ocular Oncology Center.

BACKGROUND: The Fitzpatrick Skin Type (FST) is an objective method of classifying patients based on skin color and sunburn sensitivity. The Cancer Genome Atlas (TCGA) is a method of determining the prognosis of patients with uveal melanoma based on genetic composition of the tumor. There is no literature studying the relationship of FST and TCGA groups. MATERIALS AND METHODS: Retrospective cohort study on 854 patients with uveal melanoma treated at a single tertiary ocular oncology center between April 2006 and June 2020, classified based on FST on a scale of I-VI and based on genetic analysis with TCGA classification on a scale of A, B, C, and D. Outcome measures included uveal melanoma-related metastasis and death per FST and TCGA group. RESULTS: Patients classified as FST I (compared to FST II and III-V) had higher odds of being TCGA group D (OR 2.34, p = 0.002). Patients classified as FST III-V (compared to FST I and II) had higher odds of being TCGA group B (OR 2.26, p = 0.002). Kaplan-Meier survival analysis showed no difference in melanoma-related metastasis or death comparing FST I vs. II vs. III-V within each TCGA group at 5, 10, and 15 years. CONCLUSIONS: Patients classified as FST I are more likely to have a higher grade melanoma on genetic testing whereas those classified as FST III-V show lower grade melanoma. Despite differences in tumor features and genetic profile with various FST, survival analysis at 5, 10, and 15 years revealed no difference in melanoma-related metastasis or death within each TCGA group per skin tone.